Related Experiment Video
Updated: Feb 9, 2026

Robot-Assisted Kidney Transplantation
Published on: July 19, 2021
Association Between Promoter Polymorphisms in CD46 and CD59 in Kidney Donors and Transplant Outcome
Laura A Michielsen1, Arjan D van Zuilen1, Tineke Kardol-Hoefnagel2
1Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Insights
Donor gene variations in complement proteins CD46, CD55, and CD59 impact kidney transplant success. Specific CD59 and CD46 polymorphisms are linked to rejection and reduced graft survival, potentially guiding personalized treatment strategies.
Area of Science:
- Immunogenetics
- Transplant Immunology
- Molecular Biology
Background:
- Complement regulating proteins (CD46, CD55, CD59) protect cells from damage and are expressed on donor endothelium, suggesting a role in transplant accommodation.
- Genetic variations (polymorphisms) in the promoter regions of these complement proteins may influence their expression levels.
- Investigating donor polymorphisms in complement regulatory proteins could reveal novel factors influencing kidney transplant outcomes.
Purpose of the Study:
- To determine if donor-derived polymorphisms in complement regulating proteins (CD46, CD55, CD59) affect kidney transplant outcomes.
- To analyze the association between specific promoter polymorphisms and the risk of acute rejection and graft survival.
Main Methods:
- Genotyping of five single nucleotide polymorphisms (SNPs) in the promoter regions of CD46, CD55, and CD59 in 306 kidney donors.
- Statistical analysis including hazard ratios and p-values to assess the impact of polymorphisms on rejection-free survival and graft survival.
Main Results:
- A CD59 promoter polymorphism (rs147788946) in donors was associated with significantly lower 1-year rejection-free survival and a trend towards impaired 5-year graft survival.
- Two CD46 promoter polymorphisms (rs2796267 and rs2796268) were linked to reduced rejection-free survival in recipients.
- The combined presence of favorable genotypes for CD46 (rs2796267) and CD59 (rs147788946) demonstrated a significant protective effect against acute rejection and improved graft survival.
Conclusions:
- Donor polymorphisms in CD46 and CD59 promoter regions are significant predictors of kidney transplant outcomes, influencing rejection and graft survival.
- These genetic markers can help identify recipients who may benefit from tailored immunosuppressive therapy or targeted complement inhibition strategies.
- Further research into donor immunogenetics can optimize personalized medicine approaches in organ transplantation.
Abstract:
Complement regulating proteins, including CD46, CD55, and CD59, protect cells against self-damage. Because of their expression on the donor endothelium, they are hypothesized to be involved in accommodation. Polymorphisms in their promoter regions may affect their expression. The aim of this study was to investigate if donor polymorphisms in complement regulating proteins influence kidney transplant outcomes. We included 306 kidney transplantations between 2005 and 2010. Five polymorphisms in the promoters of CD46, CD55, and CD59 were genotyped. A CD59 promoter polymorphism (rs147788946) in donors was associated with a lower 1-year rejection-free survival [adjusted hazard ratio (aHR) 2.18, 95% CI 1.12-4.24] and a trend toward impaired 5-year graft survival (p = 0.08). Patients receiving a kidney with at least one G allele for the CD46 promoter polymorphism rs2796267 (A/G) showed a lower rejection-free survival, though this became borderline significant after adjustment for potential confounders (aHR 1.87, 95% CI 0.96-3.65). A second CD46 promoter polymorphism (rs2796268, A/G), was also associated with a lower freedom from acute rejection in the presence of at least one G allele (aHR 1.95, 95% CI 1.03-3.68). Finally, the combined presence of both favorable genotypes of rs2796267 and rs147788946 had an additional protective effect both on acute rejection (p = 0.006) and graft survival (p = 0.03). These findings could help to identify patients who could benefit from intensified immunosuppressive therapy or novel complement inhibitory therapeutics.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Kidney Structure
The Eukaryotic Promoter Region
Predicting Reaction Outcomes

